Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-beta (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study
Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-beta (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study(525 views) Brescia Morra V, Alfano B, Lanzillo R, Quarantelli M, Comerci M, Marini S, Vacca G, Amato MP, Trojano M, Brunetti A, Pozzilli C
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2012 Oct; 18: 197-197.
University of Naples Federico II
Consiglio Nazionale delle Ricerche (CNR)
University of Florence
Sapienza University Rome
References: Not available.
Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-beta (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study
Not available.
Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-beta (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study
No results.
Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-beta (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study